This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Jordheim, L. P. Articles by Dumontet, C. Search for Related Content PubMed PubMed Citation Articles by Jordheim, L. P. Articles by Dumontet, C.

¹ Institut National de la Sante et de la Recherche Medicale U590, Laboratoire de Cytologie Analytique, Faculté de Médecine Rockefeller, Lyon, France and ² Unité Mixte de Recherche, Centre National de la Recherche Scientifique 8619, Institut de Biochimie et de Biophysique Moléculaire et Cellulaire, Université de Paris XI, Orsay, France

Requests for reprints: Lars P. Jordheim, Laboratoire de Cytologie Analytique, 8, Avenue Rockefeller, 69008 Lyon, France. E-mail: jordheim{at}yahoo.com

Resistance to cytotoxic nucleoside analogues is a major problem in cancer treatment. The cellular mechanisms involved in this phenomenon have been studied for several years, and some factors have been identified. However, this resistance seems to be multifactorial and more studies are needed to gain better insight into this domain. For this purpose, we developed a gemcitabine-resistant cell line (MCF7 1K) from the human mammary adenocarcinoma MCF7 strain by prolonged exposure to gemcitabine in vitro. MCF7 1K cells are highly resistant to gemcitabine (533-fold) and cross-resistance is observed with araC (47-fold), triapine (14-fold), and hydroxyurea (6.7-fold). Quantitative real-time reverse transcription-PCR and Western blot analysis showed an increase in the gene and protein expression of the large subunit of ribonucleotide reductase, R1. Ribonucleotide reductase activity was also significantly increased in the gemcitabine-resistant cells. Study of genomic DNA showed 12-fold increase in R1 gene dosage in MCF7 1K cells. In contrast, the gene and protein expression of the small subunit of ribonucleotide reductase, R2, were not modified in this cell line. These results show that gemcitabine resistance can be associated with genetic modifications of target genes in malignant cells, and suggest that the large subunit of human ribonucleotide reductase is involved in the cellular response to gemcitabine.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 4/22/05; revised 6/ 9/05; accepted 6/14/05.

This article has been cited by other articles:

				J. Cai, V. L. Damaraju, N. Groulx, D. Mowles, Y. Peng, M. J. Robins, C. E. Cass, and P. Gros Two Distinct Molecular Mechanisms Underlying Cytarabine Resistance in Human Leukemic Cells Cancer Res., April 1, 2008; 68(7): 2349 - 2357. [Abstract] [Full Text] [PDF]

				C. Rampazzo, S. Fabris, E. Franzolin, K. Crovatto, M. Frangini, and V. Bianchi Mitochondrial Thymidine Kinase and the Enzymatic Network Regulating Thymidine Triphosphate Pools in Cultured Human Cells J. Biol. Chem., November 30, 2007; 282(48): 34758 - 34769. [Abstract] [Full Text] [PDF]

				J. Wang, G. J. S. Lohman, and J. Stubbe Enhanced subunit interactions with gemcitabine-5'-diphosphate inhibit ribonucleotide reductases PNAS, September 4, 2007; 104(36): 14324 - 14329. [Abstract] [Full Text] [PDF]